Wellington Partners
TRiCares today announced the successful completion of a €22 million Series B financing round to fund the development of minimally invasive treatment of tricuspid regurgitation. Proceeds from the financing will be used to advance product development, to conduct clinical trials and to gain CE registration in Europe.
4SC AG today announced that Yakult Honsha Co. Ltd., 4SC’s development partner for resminostat in Japan, opens additional clinical centers in Japan and contributes patients to the RESMAIN study. Additionally, 4SC received a milestone payment.
Today Themis and the Coalition for Epidemic Preparedness Innovations (CEPI) announced a partnership under which Themis will provide advanced vaccine development and manufacturing for Lassa fever and MERS. The investment of up to $37,500,000 represents an innovative approach to funding vaccine development, unlocking research and development potential so that vaccines are ready for efficacy studies during an outbreak.
Page 5 of 19
